n INTRODUCTION C rystal deposition disease occurs when crystals form in joints and surrounding tissues. According to the number and size of the crystals, their deposition may induce acute inflammation and chronic cartilage damage. The most common and well known of these crystals are monosodium urate (MSU) which causes gout, calcium pyrophosphate dihydrate (CPPD) which causes acute (pseudogout) or chronic arthropathy, and basic calcium phosphate (BCP), including carbonate-substituted hydroxyapatite, octacalcium phosphate, and rarely tricalcium phosphate, which may cause chronic joint damage. Furthermore, calcium-containing crystals are thought to play an important part in progression to osteoarthritis (OA) (1) . We will review how MSU and calcium crystals form within the joints and the various factors which regulate their formation.
n CRysTal ChemIsTRy A crystal structure is defined as the particular repeating arrangement of atoms in 3-dimensional space. Usually, a crystal forms when the solubility limits are exceeded. Solubility depends on a variety of factors, including temperature, pressure, the other species present in the solution, and the perfection and size of the crystals. The first stage of crystal growth is called nucleation. This occurs when the solute molecules dispersed in the solvent start to gather into clusters. These clusters, if stable, constitute the nuclei; otherwise they re-dissolve. Therefore, the clusters need to reach a critical size in order to become stable nuclei. This is dictated by the growth conditions (temperature, supersaturation, etc.). It is at the nucleation stage that the atoms arrange themselves in the defined and periodic pattern that defines the crystal structure. According to the type of crystal structure (called Bravais lattice), crystals fall into seven different "crystal systems": triclinic, monoclinic, rhombohedral, hexagonal, orthorhombic, tetragonal and cubic. The cubic system is isotropic but the crystals of the other systems are said to be anisotropic, having two or even three refractive indexes, making them birifrangent. The crystal grows once the nuclei has achieved the critical cluster size. Nucleation and growth continue to occur simultaneously as long as supersaturation persists. Supersaturation is the driving force of crystallization. Depending on the conditions, either nucleation or growth may be the dominant force and as a result, crystals with different sizes and shapes are obtained. However, supersaturation itself is insufficient to cause crystals to form; the crystal embryos must form by collision of molecules of solute in the solution, or sometimes by the addition
of seed crystals, or other particles, or even particles from the surrounding environment. Any factors which can affect solute concentration, formation of the crystal nuclei and crystal growth around the nuclei will influence crystal formation, and will inhibit or promote crystallization.
n mONOsODIUm URaTe CRysTal meTaBOlIsm
Uric acid is the end product of purine metabolism. It is a weak organic acid that under physiological conditions is mainly found as the urate ion ( Figure 1 ). At a pH below 5.75, as may occur in the urine, the predominant form is non-ionized uric acid. Therefore, in all extracellular fluids in which pH is 7.4 and sodium is the principal cation, 98% of the uric acid is found as monosodium salt. The vast majority of mammalian species have extremely low serum urate levels (about 1 mg/dL) because uric acid is converted by uricase to allantoin, a highly soluble excretory product. By contrast, in humans in which the homolog uricase gene is structurally modified to an unexpressed state, serum urate concentrations approach the theoretical limit of solubility of urate (a concentration of 6.8 mg/dL). When the serum urate concentration exceeds the solubility of urate, supersaturation of urate in the serum and other extracellular spaces takes place. This state is defined as hyperuricemia, is required, but not solely responsible for the crystallization of MSU crystals and development of gouty arthritis. In fact, hyperuricemia is relatively common, with a prevalence of more than 10% in certain populations, but only a few people with elevated circulating uric acid develop gout (2) . These subjects, after a first stage of asymptomatic hyperuricemia, have periodic attacks of acute gout with crystal depositions in joints, followed by asymptomatic periods. Over the years, they develop chronic tophaceous gout with large deposits of crystals which damage the joints (3).
Although the different phases of the disease, as well as the mechanisms of urate crystal inflammatory response, have been extensively described over recent years, the triggering cause of MSU crystal precipitation in asyntomatic hyperuricemia has still not been identified. What can be inferred from the literature is that crystal formation and deposition is a multifactorial process. It has been shown that a number of endogenous substances and physicochemical conditions affect crystal precipitation, growth and even dissolution, regulating not only MSU crystal metabolism but also its inflammatory activity.
Factors which influence formation of MSU crystals
Various factors may influence the formation of MSU crystals affecting solubility, nucleation and crystal growth ( Figure 2 ). As mentioned above, a supersaturation of urate is needed for crystals to form. All conditions which reduce urate solubility will obviously favor crystal precipitation. Temperature, pH value, and pressure, are well known factors which affect the concentration of a solute in a solution. While pressure has hardly any effect on the solubility of urate, it has been observed that the solubility of urate decreases with a reduction in temperature (4, 5) enhancing nucleation of MSU crystals. It has been suggested that reduced solubility of urate at lower temperatures accounts for the predilection of gout in the peripheral joints, such as the foot and the ankle, which are exposed to sustained cooler temperatures. Urate solubility is affected by a lowering of the pH value, which increases the tendency of crystals to nucleate. It is known that a low pH also increases the amount of ionized calcium present in serum by reducing calcium Metabolism of crystals within the joint binding to macromolecules, phosphates, etc. (6) . Calcium ion dramatically enhances urate nucleation and growth (7) . It has been suggested that the initial nucleus may be a calcium urate, and that calcium ion readily replaces sodium ion in the salt crystal lattice. This means that any factor which lowers the pH value greatly increases the probability of urate crystallization by both a direct and, through the increase of the calcium ion activity, an indirect mechanism. Serum acidosis increases significantly with strenuous exercise, insufficient respiration and alcohol consumption (8) and these events have been reported to often trigger gout attacks. In fact, a high lactic acid content has been found in acute synovial effusions of gout (9) . It has been suggested that a local reduction in pH can be caused by phagocytosis of existing crystals and local trauma (7), or occur in intra-articular, avascular areas where glycolysis is the primary source of energy, resulting in the production of large quantities of lactic acid (10) . A study using flow cytometry to detect small amounts of crystals produced in a supersaturated solution of uric acid showed that physiological endogenous concentration of lactic acid (less than 1.0 mg/L) did not affect the formation rate, but that 2.0 mg/mL of lactic acid enhanced the formation of a mixture of MSU and uric acid crystals (11) . Examining the effect of g-globulin on urate crystal formation, the same authors showed that g-globulin accelerates the formation of MSU crystals. It is likely that these crystals have been shed from the site of their formation in the synovium or cartilage, and hence the morphology of urate crystals in synovial fluid may not be representative of the forming crystal (13) . An important study carried out in 1986 by Burt and Dutt, on the growth kinetics of MSU crystals, demonstrated that some components of cartilage and synovial fluid, such as hyaluronic acid, proteoglycan monomer and aggregate, and phosphatidylserine, had no significant effect on the growth rate constant of MSU. On the contrary, chondroitin sulphate and phosphatidylcholine increased the growth rate constant, possibly by promoting further nucleation in the growth medium (14) . IgG antibodies isolated from synovial fluid of patients suffering from gout have been shown to accelerate the appearance of new MSU crystals from a supersaturated solution of the salt in vitro. The same effect was not observed for IgG antibodies isolated from the joint fluids of patients with other joint diseases, such as pseudogout, rheumatoid arthritis or osteoarthritis, suggesting the presence of crystal-specific antibodies (15) . These antibodies would bear an imprint of the crystal surface and consequently behave as a nucleating matrix in a new crystallization event. Another well-recognized clinical feature of gout is the tendency for an acute attack to be precipitated by physical trauma, such as stubbing the toe or following physical activity. Enhanced MSU crystal nucleation has been reported in vitro following repeated snapping of urate supersaturated solutions (7). Mechanical shock caused nucleation at much lower supersaturations than those required for spontaneous nucleation. There are contrasting data on the effect of albumin on urate crystal growth. It has been reported that albumin significantly inhibited MSU crystallization (14) , increasing urate solubility. The proposed mechanism is the adsorption of the albumin molecules on the crystal surface with subsequent poisoning of the active growth sites (4).
In contrast, it was found that human serum albumin accelerates (by up to ten times) the nucleation of MSU crystals at a pH above 7.5, but only to a much lesser extent (1.2 times) at pH 7.0. Protein denaturation, as well as blocking exposed carboxylate groups on the protein, substantially reduced the nucleating effect (16) . Potassium and cupric ion slightly increase urate solubility (4). Hyaluronic acid, proteoglycan monomer and aggregate all caused very small increases in MSU solubility (14) .
Dissolution/disappearance of MSU crystals As described above, an increase in urate serum levels and, therefore, a decrease in solubility, is the first step in urate crystal formation. It is reasonable to expect that any condition leading to a decrease in hyperuricemia will promote crystal dissolution or inhibit formation of other crystals and, consequently, will trigger acute attacks of gout. This is achieved primarily by using urate-lowering drugs. MSU crystals disappear from the SF after serum uric acid is reduced to normal levels. The time required for the crystals to disappear depends on the duration of gout (17) . Sonographic signs of deposition of MSU crystals on the surface of hyaline cartilage disappeared completely once serum urate levels were stable at 6 mg/dL for seven months or more (18) with urate lowering drug therapy. However, if not treated, acute gout attacks are self-limiting. Both physical and humoral factors are involved in this process. Physical factors interfere with the initial crystal-cell interaction after binding or adsorption to urate crystals and specifically inhibit a range of cellular responses. These are represented by IgG (19) , apoB, LDL (20) , HDL (21, 22) . Humoral factors are released during the inflammatory process induced by crystals and do not have a direct effect on crystal metabolism but rather act through inhibition of specific signaling pathways which activate inflammatory genes (23) (24) (25) . These will be discussed by others in this issue of Reumatismo. (30, 31) . BCP crystal deposition may be stimulated according to extracellular availability of substrate PPi, the activity of TNAP, the availability of substrate ATP, the activity of adenosine triphosphatase (ATPases), and other factors, such as substantial local Mg2+ concentrations. It has been shown that, at low concentrations, PPi prevents the nucleation and crystal growth of hydroxyapatite (HA) and other basic calcium phosphate crystals (32) . On the other hand, the excessive PPi generation provides a source for increased extracellular Pi generation via PPi hydrolysis, and may promote BCP crystal deposition (33) . In this Factors which stimulate PPi elaboration include transforming growth factor-β (TGF-β) (34), retinoic acid (35), thyroid hormone, and ascorbate (36) . TGF-β stimulates NPP1 expression and NPP1 subcellular movement to the plasma membrane. This drives the elevation of extracellular PPi. Interleukin (IL)-1β, suppresses both NPP1 expression and extracellular PPi in chondrocytes, and blocks the effects of TGF-β on PPi (37). The insulin-like growth factor-1 (IGF-1) normally suppresses extracellular PPi in chondrocytes, thus increasing cAMP production (38) .
The role of cartilage matrix vesicles in cartilage mineralization
Recent observations have shown that cartilage matrix vesicles (MVs) are the initial site of mineral formation (39) . Cartilage MVs are extracellular cell-derived organelles whose production is modulated by hypertrophic chondrocytes (40) . MVs from OA cartilage contain enzymes necessary for Ca2+ uptakes (annexins) (41), as well as for Pi homeostasis, TNAP, 5' adenosine monophosphatase (5'AMPase), ATPases (42) , and NPP1, (43) and are able to specifically generate either CPPD and BCP crystals. Preformed crystals are then released from lumen of MVs into the extracellular matrix, so that crystals continue to grow. Although the factors regulating the quantity and type of crystal produced by these vesicles are still unknown, the state and composition of vesicle membranes is of fundamental importance in determining mineralization capacity (44 Other metabolic disorders such as hypophosphatasia, hypomagnesemic conditions (including the Gitelman's variant of Bartter's syndrome), and hemochromatosis, are linked to an increase in joint fluid PPi levels and to secondary CPPD crystal deposition disease. Mg2+ is the cofactor of TNAP. Decreased alkaline phosphatase activity due to hypomagnesemia could theoretically result in high extracellular levels of PPi and, therefore, in an increase in the ionic product PPixCa2+ which predisposes to CPPD crystal deposition (52) . Hypophosphatasia is due to deficient activity of the ectoenzyme TNAP, the major physiological antagonist of the NPP1-mediated elevation of extracellular PPi (50) . Factors which affect the solubility of calcium crystals also indirectly affect the shedding of crystals from cartilage. The level of ionized calcium appears to be the most important regulator of CPPD crystal dissolution while the PPi concentration has relatively little effect (53) . When Ca2+ levels decrease (below 5 mg/100 mL), a rapid increase in CPPD solubility occurs. Crystals become smaller and are shed into the joint space where they can cause an acute inflammatory episode of pseudogout.
In conclusion, bioregulation of PPi levels in cartilage is clearly an important factor in maintaining tissue integrity and function. The homeostatic mechanisms involved in maintenance of physiological PPi levels are complex and involve several factors: aging, growth factors, chemokines, transporters, enzymes, and enzyme substrates. A understanding of the pathophysiology of crystal formation will contribute to the prevention and treatment of pathological crystal deposition disease.
n ReFeReNCes
